More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

With a $3-billion strategic alliance with Sumitomo Dainippon Pharma in the offing, Vivek Ramaswamy, CEO and founder of Roivant Sciences, is looking to take its “hub and spoke” business model for drug development to the next level. Inside Roivant...

The US Congressional Budget Office and the staff of the Joint Committee on Taxation have provided an analysis of the proposed drug pricing plan highlighted last month by US House of Representatives Speaker Nancy Pelosi (D-Calif.). What do they see...

Of the 12,300 medicines used in the UK, around 7,000 come from or via the European Union (EU), so what happens if the UK is not able to negotiate a deal as it faces an October 31 deadline to withdraw from the EU? How are the UK and the...

What’s behind continuing investment in manufacturing capabilities for high-potency APIs (HPAPIs)? The potential in innovator drugs is a driving factor, but the supply opportunities for generic drugs with HPAPIs also comes into play. High-potency...

What are the key developments in bio/pharmaceutical manufacturing? From large-scale biomanufacturing projects, to mergers and acquisitions involving cell and gene therapy production, to continuous manufacturing, DCAT Value Chain Insights looks at...

New digital tools hold the potential to transform the pharma customer–supplier relationship, but how? In DCAT Sharp Sourcing LIVE, a livestreamed webinar on Oct. 10, learn how artificial intelligence, the IoT, blockchain technology, and advanced...

Which CDMOs and CMOs are making the mark in terms of deal-making and expansions and what manufacturing sectors are seeing the greatest activity? DCAT Value Chain Insights rounds up the key investments by CDMOs/CMOs making the news. Key activity in...